New study looks at long-term drug costs for treating AIDS in Brazil

Nov 13, 2007

AIDS continues to be a staggering global public health problem. The World Health Organization estimates that two million people in developing countries receive treatment known as HAART (highly active antiretroviral therapy), more commonly known as “AIDS cocktails.”

This number represents just 25% of those in need of treatment in these countries. However, little is known about the long-term costs associated with providing drugs to AIDS patients in developing countries. To study those long-term cost trends, researchers from the Harvard School of Public Health have performed the first detailed analysis of AIDS drug cost trends in Brazil. The results appear in the November 13, 2007 issue of the journal PLOS Medicine.

Brazil has one of the developing world’s oldest, largest and most successful AIDS treatment programs and has been treating AIDS patients for more than a decade. Brazil provides free and universal access to AIDS drugs and is a model for other countries scaling up AIDS treatment.

The results showed that, although costs for Brazil’s locally produced generic antiretroviral drugs (ARVs) increased from 2001 to 2005, the country still saved approximately $1 billion in that time period through controversial price negotiations with multinational pharmaceutical companies for patented ARVs. Since 2001, Brazil has been able to obtain lower prices for patented ARVs by threatening to produce AIDS drugs locally. Though these negotiations initially prompted major declines in AIDS drug spending, HAART costs in Brazil more than doubled from 2004 to 2005. The steep increase reflects the fact that more people living with HIV/AIDS began treatment and are living longer. The increase also reflects the challenges associated with providing complex, costly second- and third-line treatments as people develop resistance to first-line drugs, live longer and require more complex treatment regimens.

“Although Brazil has saved large sums by negotiating with pharmaceutical companies, it faces significant challenges with the rising cost of providing universal access to AIDS treatment,” said Amy Nunn, lead author of the study and formerly a researcher at HSPH. “Brazil’s challenges may foreshadow the rising costs other developing countries will face as they work to provide universal access to treatment for all people living with HIV/AIDS. The Brazilian experience suggests that if the global community is truly committed to providing high-quality treatment to all people living with HIV/AIDS, far more resources must be mobilized to achieve this important goal.”

Source: Harvard School of Public Health

Explore further: Scientists discover how a killer fungus attacks HIV patients

add to favorites email to friend print save as pdf

Related Stories

Can science eliminate extreme poverty?

Apr 16, 2014

Science has often come to the rescue when it comes to the world's big problems, be it the Green Revolution that helped avoid mass starvation or the small pox vaccine that eradicated the disease. There is ...

Romania keeps ancient tradition of bee medicine alive

Apr 10, 2014

Bee venom to combat multiple sclerosis, pollen for indigestion, honey to heal wounds—the humble bee has been a key source of alternative medicines since ancient times, and Romania is working to keep the ...

Science, not muscle, driving many Olympic wins

Feb 14, 2014

Nineteen-year-old Slovakian luger Josef Petrulak competed in the Sochi Olympics in a 22-year-old sled. That's right: His sled is three years older than he is. His German rivals get a new sled every year, ...

Hookworm genome sequenced

Jan 19, 2014

Going barefoot in parts of Africa, Asia and South America contributes to hookworm infections, which afflict an estimated 700 million of the world's poor. The parasitic worm lives in the soil and enters the body through the ...

Recommended for you

Harm-reduction program optimizes HIV/AIDS prevention

Apr 21, 2014

(Medical Xpress)—New research from UC San Francisco and the San Francisco AIDS Foundation has found that clients participating in a harm-reduction substance use treatment program, the Stonewall Project, decrease their use ...

User comments : 0

More news stories

Man among first in US to get 'bionic eye' (Update)

A degenerative eye disease slowly robbed Roger Pontz of his vision. Diagnosed with retinitis pigmentosa as a teenager, Pontz has been almost completely blind for years. Now, thanks to a high-tech procedure ...